Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.615 -0.045 (-2.71%)

Streaming Delayed Price Updated: 1:52 PM EDT, Jun 25, 2026 Add to My Watchlist

Price and Volume

Volume	1,064,867
Open	1.680
Bid (Size)	1.610 (5,500)
Ask (Size)	1.620 (4,000)
Prev. Close	1.660
Today's Range	1.600 - 1.690
52wk Range	1.220 - 3.535
Shares Outstanding	60,705,391
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

June 12, 2026

From Equity Insider

Via GlobeNewswire

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

June 11, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	+1.6%	+1.6%
1 Month	-25.2%	-25.2%
3 Month	-14.1%	-14.1%
6 Month	-6.1%	-6.1%
1 Year	+14.5%	+14.5%

More News

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

June 11, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗

June 09, 2026

Via MarketBeat

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗

November 03, 2025

Via Stocktwits

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 27, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

May 12, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 07, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

May 05, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

March 31, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 05, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

February 12, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

February 04, 2026

From Caribou Biosciences, Inc.

Via GlobeNewswire

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

December 24, 2025

From Equity Insider

Via GlobeNewswire

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

December 01, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

November 03, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside

November 03, 2025

Via AB Newswire

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

November 03, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

November 03, 2025

From Caribou Biosciences, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?

Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Caribou Biosciences, Inc. - Common Stock trade on?

Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?

The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market

What is the current price of Caribou Biosciences, Inc. - Common Stock?

The current price of Caribou Biosciences, Inc. - Common Stock is 1.615

When was Caribou Biosciences, Inc. - Common Stock last traded?

The last trade of Caribou Biosciences, Inc. - Common Stock was at 06/25/26 01:52 PM ET

What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?

The market capitalization of Caribou Biosciences, Inc. - Common Stock is 98.04M

How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?

Caribou Biosciences, Inc. - Common Stock has 98M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.